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Introduction:
Osteoarthritis (OA) is a degenerative joint disease characterised by progressive destruction of cartilage and bone with a
high prevalence in horses. It causes pain, lameness and functional disability and is therefore economically important.
Existing treatment options are limited and often base on pain reduction. Research on bioactive collagen peptides® (BCP)
demonstrated its stimulating effect on cartilage tissue in in vitro and in vivo (mice) studies. The aim of this orientation
study was to test if oral BCP supplementation has the potency to mend OA in horses.
Animals, materials and methods:
38 privately owned horses with mild to moderate OA were available for the two-centred study. In one centre 18 of these
patients (6±3 years old; 519±100kg BW) received either 25g (n=6) or 50g (n=12) BCP/day orally for 12 weeks. In the
second centre 20 horses (18±4; 413±94kg BW) received either a placebo (Con; maltodextrine; n=10) or 25g BCP/day.
The attending veterinarian performed an orthopaedic examination, a flexion test and evaluated the degree of lameness,
rotation pain, step length and arc of flight during trot (8 parameters) at the beginning and after 6 and 12 weeks of the
trial. The owners answered a weekly questionnaire about their perception of lameness, mobility and the horses’
willingness to move. Statistical significance of the differences between the 3 groups (25g, 50g, Con) were tested




OA is a chronic degenerative disease threatening for the animals and their owners because it is one of the major
reasons to force the equine athlete into retirement. Hitherto, treatment methods were limited mostly to pain management
without proper options to halt the degenerative processes or even cure the disease. Experimental information and
clinical observations in other species such as humans and rats led to the testing of the active substance BCP© also in
chronically affected horses. The results of this pilot study give good reason to further investigate the effects of oral BCP
administration on the symptoms of OA in horses. The outcome of this investigation especially after 12 weeks of
supplementation of the higher dosage (50g/d) of this safe food component in equine patients with chronic OA is
promising. Further blinded and placebo controlled long-term investigations on BCP efficacy in horses with OA, preferably
with maximally objective parameters, are needed to confirm these first positive results of BCP treatment.
   Cohen r Wilcoxon p
ground parameter change 
basic vs 
week 
Placebo 25 50 Placebo 25 50
 lameness 6 0.14 0.24 0.56 1.000 0.205 0.004** 
 12 0.00 0.27 0.58 1.000 0.297 0.002** 
 flexion test 6 0.14 0.17 0.61 1.000 0.438 0.004** 
 12 0.22 0.33 0.62 1.000 0.125 0.001*** 
hard rotation 
pain 
6 0.22 0.43 0.46 0.625 0.031* 0.031* 
hard 12 0.22 0.19 0.55 1.000 0.375 0.008* 
soft 6 0.32 0.25 0.40 0.500 0.289 0.070 
soft 12 0.39 0.12 0.54 0.250 0.609 0.016** 
hard step length 
trot 
6 0.00 0.32 0.46 1.000 0.219 0.063 
hard 12 0.00 0.48 0.50 1.000 0.016** 0.031* 
soft 6 0.11 0.35 0.50 1.000 0.125 0.031* 
soft 12 0.00 0.50 0.54 1.000 0.016** 0.016** 
hard arc of flight 
trot 
6 0.29 0.18 0.50 1.000 0.625 0.031* 
hard 12 0.24 0.45 0.58 0.625 0.031* 0.008* 
soft 6 0.17 0.41 0.50 1.000 0.063 0.031* 
soft 12 0.27 0.36 0.50 1.000 0.125 0.031* 
 
Data of all 38 horses from both centers were evaluated together. As expected, no adverse effects have been observed.
In the 50g group in 6/8 parameters a strong effect (Cohen r>0.5) was detected between beginning and end of the trial,
with 2 parameters (lameness, flexion pain) significantly improved already after 6 weeks (Table). In the 25g group a
moderate effect (Cohen d=0.3-0.5) was seen in 6 para-
meters, with 3 parameters improved already after 6 weeks.
The evaluation of the owners’ answers revealed a strong
effect for the factors mobility and willingness to move (Fig.,
Cohen r 0.69 and 0.62, respectively) in the 50g group and
a moderate effect (Cohen r=0.49) for the development of
lameness in both BCP groups when compared to the pla-
cebo treatment (group Con), all significant in the Mann-
Whitney-U-test. The 25g dosage showed a moderate im-
provement (r=0.41) of the lameness.
Table: Cohen r and p values (post-hoc test) describing the changes of
parameters describing symptoms of OA in horses between basic examination
and after 6 weeks and 12 weeks of supplementing a placebo or 25g and 50g




per week in the 38
horses of the
groups supple-
mented with 25 or
50g of BCP and
placebo as per-
ceived by the
owners
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